Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jan 17;11:338. doi: 10.1038/s41467-019-14219-6

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 5 — a RNA-seq was performed in triplicate on LNCaP-AI/tet-MUC1shRNA (left) and DU-145/tet-MUC1shRNA (right) cells treated with vehicle or 500 ng/ml DOX for 7 days. The datasets were analyzed with GSEA, using the Hallmark gene signature collection for the p53 Pathway. b RNA-seq was performed in triplicate on LNCaP-AI/tet-MUC1shRNA (left) and DU-145/tet-MUC1shRNA (right) cells treated with vehicle or 500 ng/ml DOX for 7 days. The datasets were analyzed with GSEA, using the Hallmark gene signature collection for E2F Targets. c and d. LNCaP cells expressing tet-MUC1-C were treated with vehicle or 500 ng/ml DOX for 7 days. MUC1-C, BRN2 and SOX2 mRNA levels were analyzed by qRT-PCR (c). The results (mean±SD of three determinations) are expressed as relative mRNA levels compared to that obtained for vehicle-treated cells (assigned a value of 1). Lysates were immunoblotted with antibodies against the indicated proteins (d). e and f LNCaP-AI cells stably expressing a tet-CshRNA or tet-MUC1shRNA were treated with vehicle or 500 ng/ml DOX for 7 days. SOX2 mRNA levels were analyzed by qRT-PCR (e). The results (mean±SD of five determinations) are expressed as relative mRNA levels compared to that obtained for DOX-treated LNCaP-AI/tet-CshRNA cells (assigned a value of 1). Lysates were immunoblotted with the indicated antibodies (f). g Lysates from DU-145/tet-CshRNA and DU-145/tet-MUC1shRNA cells treated with vehicle or 500 ng/ml DOX for 7 days were immunoblotted with antibodies against the indicated proteins. h Lysates from DU-145/CshRNA and DU-145/BRN2shRNA cells were immunoblotted with antibodies against the indicated proteins. *p < 0.05 (Student’s t-test). Source data are provided as a Source Data file.